WS
CYTK icon

Wedbush Securities’s Cytokinetics CYTK Stock Holding History

Wedbush Securities’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-15,490
Closed -$101K – 635
2013
Q4 		$101K Buy
15,490
+5,418
+54% +$35.6K 0.02% 528
2013
Q3 		$76K Buy
+10,072
New +$108K 0.02% 525

Other funds holding CYTK

LPLP
Lansdowne Partners Limited Partnership London, United Kingdom $11.9B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Wedbush Securities's CYTK Position: Q1 2014 in Review

Wedbush Securities sold out of Cytokinetics (CYTK) in Q1 2014, closing a stake of 15,490 shares — an estimated $101K sold.

Wedbush Securities first reported a position in CYTK in Q3 2013 and held it in 2 quarters. The position peaked at $101K in Q4 2013. 109 funds tracked by Wall St. Rank hold CYTK as of Q1 2014.

  • Wedbush Securities reported no remaining Cytokinetics position as of Q1 2014 after selling out during the quarter.
  • Wedbush Securities sold 15,490 Cytokinetics shares in Q1 2014, an estimated $101K.
  • Wedbush Securities first reported a position in Cytokinetics in Q3 2013 and held it in 2 quarters.
  • Wedbush Securities's Cytokinetics position peaked at $101K in Q4 2013.
  • 109 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2014.

Based on Wedbush Securities's 13F filing for Q1 2014, filed 9 May 2014.